loading page

Effects of Mirabegron on JJ Stent-Related Symptoms: A Multicentric Study
  • +10
  • Onder Cinar,
  • Yiloren Tanidir,
  • Selcuk Ozer,
  • Sezer Cizmeci,
  • Oguzcan Erbatu,
  • Turan Ozdemir,
  • Reha Girgin,
  • Sakir Ongun,
  • Oktay Ucer,
  • Fuat Kizilay,
  • Volkan Sen,
  • Bora Irer,
  • Ozan Bozkurt
Onder Cinar
Zonguldak Bulent Ecevit University
Author Profile
Yiloren Tanidir
Author Profile
Selcuk Ozer
Dokuz Eylul Universitesi Hastanesi
Author Profile
Sezer Cizmeci
Author Profile
Oguzcan Erbatu
Manisa Celal Bayar Universitesi
Author Profile
Turan Ozdemir
Author Profile
Reha Girgin
Author Profile
Sakir Ongun
Balikesir University
Author Profile
Oktay Ucer
Author Profile
Fuat Kizilay
Author Profile
Volkan Sen
Manisa State Hospital
Author Profile
Bora Irer
Izmir Metropolitan Municipality Esrefpasa Hospital
Author Profile
Ozan Bozkurt
Dokuz Eylül University
Author Profile

Abstract

Purpose: To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Methods: Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analyzed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative seventh day, and again after at least three weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. Results: The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (p < 0.0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (p < 0.0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (p < 0.0001), and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (p < 0.0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (p < 0.0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (p < 0.0001), and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (p < 0.0001). Conclusion: Daily use of 50g of mirabegron significantly improved stent-related symptoms, sexual matters, and quality of life.

Peer review status:Published

22 Oct 2020Submitted to International Journal of Clinical Practice
24 Oct 2020Assigned to Editor
24 Oct 2020Submission Checks Completed
26 Oct 2020Reviewer(s) Assigned
04 Nov 2020Review(s) Completed, Editorial Evaluation Pending
16 Nov 2020Editorial Decision: Accept
23 Nov 2020Published in International Journal of Clinical Practice. 10.1111/ijcp.13857